China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal injection suspension (ARVN001) in a patient with uveitis macular edema (UME) at the Boao Super Hospital in Hainan’s medical pilot zone. This marks the first application of suprachoroidal injection therapy in Lecheng, facilitated by the region’s “first pilot, first trial” policy, just half a year after its commercial launch in the US.
Drug Overview and Development
ARVN001, originally developed by Clearside Biomedical, is a patented suspension of glucocorticoid triamcinolone acetonide (trade name: Xipere) designed for suprachoroidal injection administration. The drug has been approved in the US for the treatment of UME and is being developed to treat diabetic macular edema (DME) and other fundus diseases. Arctic Vision obtained exclusive development and commercialization rights to ARVN001 from Clearside in Greater China and South Korea in March 2020. The deal was expanded to include ten ASEAN countries and India in August 2021, and Australia and New Zealand one month later.
Clinical Progress and Future Outlook
The drug received approval for study in DME in China in September 2021 and was first dosed in a Phase III study in China for UME in November 2022. The first injection in China highlights Arctic Vision’s commitment to advancing innovative ophthalmic therapies and addressing significant unmet needs in the treatment of UME and related conditions.-Fineline Info & Tech
